O	0	6	Effect
O	7	9	of
B-intervention	10	20	myofascial
I-intervention	21	31	techniques
O	32	35	for
O	36	45	treatment
O	46	48	of
B-condition	49	59	persistent
I-condition	60	63	arm
I-condition	64	68	pain
O	69	74	after
O	75	81	breast
O	82	88	cancer
O	89	98	treatment
O	98	99	:
O	100	110	randomized
O	111	121	controlled
O	122	127	trial
O	127	128	.

O	129	131	To
O	132	143	investigate
O	144	147	the
O	148	154	effect
O	155	157	of
O	158	168	myofascial
O	169	176	therapy
O	177	179	in
O	180	188	addition
O	189	191	to
O	192	193	a
O	194	202	standard
O	203	211	physical
O	212	219	therapy
O	220	227	program
O	228	231	for
O	232	241	treatment
O	242	244	of
O	245	255	persistent
O	256	259	arm
O	260	264	pain
O	265	270	after
O	271	280	finishing
O	281	287	breast
O	288	294	cancer
O	295	304	treatment
O	304	305	.

O	306	312	Double
O	312	313	-
O	313	320	blinded
O	321	322	(
O	322	329	patient
O	330	333	and
O	334	342	assessor
O	342	343	)
O	344	354	randomized
O	355	365	controlled
O	366	371	trial
O	371	372	.

O	373	383	University
O	384	393	Hospitals
O	394	400	Leuven
O	400	401	,
B-location	402	409	Belgium
O	409	410	.

O	411	412	A
O	413	418	total
O	419	421	of
B-total-participants	422	424	50
B-eligibility	425	433	patients
I-eligibility	434	438	with
I-eligibility	439	449	persistent
I-eligibility	450	453	arm
I-eligibility	454	458	pain
I-eligibility	459	462	and
I-eligibility	463	473	myofascial
I-eligibility	474	486	dysfunctions
I-eligibility	487	492	after
I-eligibility	493	499	breast
I-eligibility	500	506	cancer
I-eligibility	507	516	treatment
O	516	517	.

O	518	522	Over
O	523	528	three
O	529	535	months
O	535	536	,
O	537	540	all
O	541	549	patients
O	550	558	received
O	559	560	a
O	561	569	standard
O	570	578	physical
O	579	586	therapy
O	587	594	program
O	594	595	.

O	596	599	The
O	600	612	intervention
O	613	618	group
O	619	627	received
O	628	630	in
O	631	639	addition
O	640	642	12
O	643	651	sessions
O	652	654	of
O	655	665	myofascial
O	666	673	therapy
O	673	674	,
O	675	678	and
O	679	682	the
O	683	690	control
O	691	696	group
O	697	705	received
O	706	708	12
O	709	717	sessions
O	718	720	of
B-control	721	728	placebo
I-control	729	736	therapy
O	736	737	.

O	738	742	Main
O	743	750	outcome
O	751	761	parameters
O	762	766	were
B-outcome-Measure	767	771	pain
I-outcome-Measure	772	781	intensity
O	782	783	(
O	783	790	primary
O	791	798	outcome
O	798	799	)
O	800	801	(
O	801	808	maximum
O	809	815	visual
O	816	824	analogue
O	825	830	scale
O	831	832	(
O	832	835	VAS
O	835	836	)
O	837	838	(
O	838	839	0
O	839	840	-
O	840	843	100
O	843	844	)
O	844	845	)
O	845	846	,
B-outcome-Measure	847	857	prevalence
I-outcome-Measure	858	862	rate
I-outcome-Measure	863	865	of
I-outcome-Measure	866	869	arm
I-outcome-Measure	870	874	pain
O	874	875	,
B-outcome-Measure	876	884	pressure
I-outcome-Measure	885	901	hypersensitivity
O	902	903	(
O	903	911	pressure
O	912	916	pain
O	917	927	thresholds
O	928	929	(
O	929	931	kg
O	931	932	/
O	932	935	cm2
O	935	936	)
O	937	940	and
B-outcome-Measure	941	945	pain
I-outcome-Measure	946	953	quality
O	954	955	(
O	955	961	McGill
O	962	966	Pain
O	967	980	Questionnaire
O	980	981	)
O	981	982	.

O	983	991	Measures
O	992	996	were
O	997	1002	taken
O	1003	1009	before
O	1010	1013	and
O	1014	1019	after
O	1020	1023	the
O	1024	1036	intervention
O	1037	1040	and
O	1041	1043	at
O	1044	1048	long
O	1049	1053	term
O	1054	1055	(
O	1055	1056	6
O	1057	1060	and
O	1061	1063	12
O	1064	1070	months
O	1071	1077	follow
O	1077	1078	-
O	1078	1080	up
O	1080	1081	)
O	1081	1082	.

O	1083	1091	Patients
O	1092	1094	in
O	1095	1098	the
O	1099	1111	intervention
O	1112	1117	group
O	1118	1121	had
O	1122	1123	a
O	1124	1137	significantly
O	1138	1145	greater
O	1146	1154	decrease
O	1155	1157	in
B-outcome	1158	1162	pain
I-outcome	1163	1172	intensity
O	1173	1181	compared
O	1182	1184	to
O	1185	1188	the
O	1189	1196	control
O	1197	1202	group
O	1203	1204	(
O	1204	1207	VAS
O	1208	1209	-
O	1209	1211	44
O	1211	1212	/
O	1212	1215	100
O	1216	1218	vs
O	1218	1219	.
O	1220	1221	-
O	1221	1223	24
O	1223	1224	/
O	1224	1227	100
O	1227	1228	,
O	1229	1230	P
O	1231	1232	=
O	1233	1234	0
O	1234	1235	.
O	1235	1238	046
O	1238	1239	)
O	1240	1244	with
O	1245	1246	a
O	1247	1251	mean
O	1252	1262	difference
O	1263	1265	in
O	1266	1272	change
O	1273	1278	after
O	1279	1284	three
O	1285	1291	months
O	1292	1299	between
O	1300	1306	groups
O	1307	1309	of
O	1310	1312	20
O	1312	1313	/
O	1313	1316	100
O	1317	1318	(
O	1318	1320	95
O	1320	1321	%
O	1322	1332	confidence
O	1333	1341	interval
O	1341	1342	,
O	1343	1344	0
O	1344	1345	.
O	1345	1346	4
O	1347	1349	to
O	1350	1352	39
O	1352	1353	.
O	1353	1354	7
O	1354	1355	)
O	1355	1356	.

O	1357	1362	After
O	1363	1366	the
O	1367	1379	intervention
O	1379	1380	,
B-iv-bin-percent	1381	1383	44
I-iv-bin-percent	1383	1384	%
O	1385	1391	versus
B-cv-bin-percent	1392	1394	64
I-cv-bin-percent	1394	1395	%
O	1396	1398	of
O	1399	1407	patients
B-outcome	1408	1413	still
I-outcome	1414	1425	experienced
I-outcome	1426	1430	pain
O	1431	1433	in
O	1434	1437	the
O	1438	1450	intervention
O	1451	1454	and
O	1455	1462	control
O	1463	1468	group
O	1468	1469	,
O	1470	1482	respectively
O	1483	1484	(
O	1485	1486	P
O	1487	1488	=
O	1489	1490	0
O	1490	1491	.
O	1491	1494	246
O	1494	1495	)
O	1495	1496	.

O	1497	1499	No
O	1500	1511	significant
O	1512	1523	differences
O	1524	1528	were
O	1529	1534	found
O	1535	1538	for
O	1539	1542	the
O	1543	1548	other
O	1549	1557	outcomes
O	1557	1558	.

O	1559	1569	Myofascial
O	1570	1577	therapy
O	1578	1580	is
O	1581	1583	an
O	1584	1593	effective
O	1594	1602	physical
O	1603	1610	therapy
O	1611	1619	modality
O	1620	1622	to
O	1623	1631	decrease
O	1632	1636	pain
O	1637	1646	intensity
O	1647	1649	at
O	1650	1653	the
O	1654	1657	arm
O	1658	1660	in
O	1661	1667	breast
O	1668	1674	cancer
O	1675	1684	survivors
O	1685	1687	at
O	1688	1693	three
O	1694	1700	months
O	1700	1701	,
O	1702	1705	but
O	1706	1708	no
O	1709	1714	other
O	1715	1723	benefits
O	1724	1726	at
O	1727	1731	that
O	1732	1736	time
O	1737	1741	were
O	1742	1747	found
O	1747	1748	.

O	1749	1754	There
O	1755	1759	were
O	1760	1762	no
O	1763	1767	long
O	1767	1768	-
O	1768	1772	term
O	1773	1780	effects
O	1781	1783	at
O	1784	1786	12
O	1787	1793	months
O	1794	1800	either
O	1800	1801	.
